Guggenheim analyst Brad Canino assumed coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $18 price target The company’s ORIC-944 has potentially best-in-class properties for the emerging PRC2 inhibitor class for prostate cancer, the analyst tells investors in a research note. The firm believes this thesis may become validated in the near-term with a first Pfizer (PFE) mevrometostat Phase 3 readout.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals’ ORIC-944: A Promising PRC2 Inhibitor with Strategic Partnerships and Market Potential
- ORIC Pharmaceuticals Reports Q2 2025 Financial Results
- Oric Pharmaceuticals appoints Kevin Brodbeck CTO
- Oric Pharmaceuticals: Promising Future with Key Trials and Financial Stability Underpinning Buy Rating
- Oric Pharmaceuticals price target lowered to $19 from $22 at H.C. Wainwright